 | Up a level |
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J. L., Motoyama, S., Lievre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zhang, J., Zhu, L., Lei, M., Kondo, K., Cleary, J. M. and Moehler, M. (2020). Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study. Ann. Oncol., 31. S. S1193 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Moehler, M., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lievre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zhang, J., Soleymani, S., Lei, M., Kondo, K., Cleary, J. and Kelly, R. J. (2021). Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577. Ann. Oncol., 32. S. S1045 - 3. AMSTERDAM: ELSEVIER. ISSN 1569-8041